May 2nd 2024
The new research will compare eblasakimab to dupilumab and lebrikizumab.
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Medical Crossfire®: Maximizing Patient Outcomes in Shingles – Are You Leveraging Guideline Based Care?
View More
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa
View More
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
The Cutaneous Connection: Atopic Dermatitis for Adolescents During Changing Weather
October 17th 2022In this episode, Jeffrey M. Cohen, MD, a board-certified medical dermatologist and the director of the Psoriasis Treatment Program at the Yale School of Medicine, discusses treatment options for adolescents with atopic dermatitis, how the changing seasons can affect flare-ups, and what caregivers can do at home to help prevent extreme itching.
Real-World Study Shows Dupixent Improves AD Symptoms in Children Under 12 Years
October 11th 2022A real-world study of children with moderate-to-severe atopic dermatitis (AD) in China found Dupixent can reduce symptoms and improve pruritus. Traditional therapies had little effect, according to the researchers.
Patients With Moderate-to-Severe Atopic Dermatitis Experience Impaired QOL, Feel Disease Burden
September 21st 2022A national study in Germany identified the baseline characteristics of patients with moderate-to-severe atopic dermatitis (AD) to understand how they are usually treated with Dupixent in the real world.
Joshua Zeichner, MD; Brittany Craiglow, MD; Elizabeth Swanson, MD; Vikash Oza, MD; and Raj Chovatiya, MD, PhD, provide take-home messages for dermatologists treating pediatric patients with atopic dermatitis.
Case 3 Continued: How to Have Conversation About Risk of Biologics and Length of Therapy
Atopic dermatitis specialists discuss how to have a conversation with parents about risks of biologics and how to answer questions about length of therapy.
Case 2 Continued: Importance of Combination Therapy and Shared Decision Making
Expert pediatric dermatologists discuss the importance of combination therapy and shared decision-making when treating pediatric patients with atopic dermatitis.
Case 2 Continued: Addressing Injectable Medications in Children
Joshua Zeichner, MD; Brittany Craiglow, MD; Elizabeth Swanson, MD; and Vikash Oza, MD, address techniques for injectables when treating pediatric patients with atopic dermatitis.
Case 1 Continued: Treatments Beyond Topical Agents and the Use of Dupixent
Joshua Zeichner, MD; Brittany Craiglow, MD; Elizabeth Swanson, MD; Vikash Oza, MD; and Raj Chovatiya, MD, PhD, discuss treatments beyond topical agents and the use of dupilumab in pediatric patients with atopic dermatitis.
Clinical Presentations of Pediatric AD and Shin Guard Dermatitis
August 23rd 2022Peter Lio, MD, clinical professor of dermatology and pediatrics at Northwestern University Feinberg School of Medicine in Chicago, Illinois, discusses how atopic dermatitis presents differently in pediatric patients, and the 2021 allergen of the year, acetophenone azine associated with shin guard dermatitis.